Acute Porphyria Drug Database

Monograph

B01AC17 - Tirofiban
Not porphyrinogenic
NP

Rationale
No data pointing to CYP-interactions.
Chemical description
Butylsulfonyl phenyalanine platelet inhibitor. Given together with ASA and heparin as intravenous infusion 0.4 ug/kg BW/ min to prevent early infarction in instable angina and other cardiac conditions.

Similar drugs
Explore alternative drugs in similar therapeutic classes B01A / B01AC or go back.

Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia). Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway). What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.
Netherlands
Aggrastat · Aggrastat 0,05 mg/ml oplossing, oplossing voor intraveneuze infusie · Aggrastat 0,25 mg/ml concentraat, concentraat voor oplossing voor intraveneuze infusie
Belgium
Aggrastat · Aggrastat 0.05 mg/ml sol. perf. i.v. · Aggrastat 0.25 mg/ml sol. perf. (à diluer) i.v. flac.
United Kingdom
Aggrastat · Aggrastat 12.5mg/250ml infusion bags · Aggrastat 12.5mg/50ml concentrate for solution for infusion vials · Tirofiban · Tirofiban 12.5mg/250ml infusion bags
Norway
Tirofiban ibisqus
Luxembourg
AGGRASTAT
Finland
Aggrastat
Latvia
Aggrastat
 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙